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Abstract Growth failure associated with severe primary
insulin-like growth factor 1 (IGF-1) deficiency (SPIGFD),
a condition defined as basal IGF-1 standard deviation score
(SDS) less than or equal to -3 and height SDS less than or
equal to -3 in a child with normal or elevated levels of
growth hormone, can be successfully treated with the
recombinant human IGF-1 mecasermin. In this review, we
describe the most safe and effective way to use mecasermin
in the treatment of patients with SPIGFD, including how to
initiate dosing, key side effects, and how to monitor
treatment. Finally, mention of how to reinitiate therapy is
made, given the recent drug shortage with mecasermin.
Key Points
It is important to achieve a stable therapeutic dose,
ideally within 1 month, as both first-year growth and
long-term outcomes are best at doses C0.1 mg/kg/
dose given twice daily.
Extensive family discussions are needed to
emphasize the importance of compliance and
monitoring for side effects.
Doses should be adjusted for weight gain at regular
intervals as growth progresses.
1 Introduction
Many genes and environmental factors affect post-natal
growth; however, the growth hormone (GH)/insulin-like
growth factor-1 (IGF-1) axis is one of the most important
[1, 2]. IGF-1 is a 70-amino acid peptide hormone and
growth factor that is structurally homologous to proinsulin.
Its metabolic actions leading to growth and other anabolic
effects include insulin-like actions such as stimulation of
glucose uptake, glycogen synthesis, amino acid transport,
and an increase in net protein synthesis [3]. In normal
individuals, IGF-1 circulates as part of a ternary complex
with a molecular weight of 150 kDa. The complex consists
of IGF-1 itself, an acid-labile subunit (ALS), and a protein
that binds IGF-1 (IGFBP-3). Serum levels of both ALS and
IGFBP-3 are also dependent on the presence of normal GH
secretion [4]. The half-life of the 150 kDa complex is
approximately 18–20 h [5], while that of free IGF-1 is
approximately 4 h [6].
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In normal children, GH is the major regulator of circu-
lating IGF-1. Because GH provocative testing is complex,
many physicians begin the evaluation of a short child by
measuring serum IGF-1 and IGFBP-3, and evaluate GH
production only in those with low IGF-1 levels. However,
there are instances where the information provided by the
IGF-1 and GH tests is discordant. That is, a child with
normal or high GH secretion may have low IGF-1 levels.
Rosenfeld [7] proposed the term ‘primary IGF deficiency’
to describe these patients, and ‘secondary IGF deficiency’
to describe children with low IGF-1 levels due to GH
deficiency. This definition is consistent with other endo-
crine systems consisting of a trophic and peripherally
active hormone [8]. A comprehensive recent review of
IGF-1 deficiency (IGFD) by Savage is also available [9].
In an analysis of the pivotal study for mecasermin,
Chernausek et al. [10] showed that treatment with
recombinant human IGF-1 (rhIGF-1) was effective in
promoting growth in children with severe primary IGFD
(SPIGFD) due to GH insensitivity. IGF-1, Increlex
(mecasermin [rDNA origin]) manufactured by Ipsen
Biopharmacueticals, Inc., has marketing authorization by
the US FDA and the European Medicines Agency (EMA)
for the treatment of children with SPIGFD, and by the
FDA for the treatment of children with GH gene deletion
who have developed neutralizing antibodies to recombi-
nant GH. There are some differences in the SPIGFD
definition in the US versus Europe based on the level of
circulating IGF-1(less than or equal to -3 standard
deviation score [SDS] in the US and\2.5th percentile for
age and gender in the EU); both require the height SDS to
be less than or equal to -3, GH to be sufficient and, in the
EU, the label specifically requires the exclusion of sec-
ondary forms of IGFD.
2 Diagnosis of Severe Primary Insulin-Like Growth
Factor 1 (IGF-1) Deficiency
Early recognition of growth disorders can come from
several sources and is often a result of parental concern.
Ideally, a growth chart maintained by the primary care
physician provides a record of the pattern of growth, which
can determine the need for further evaluation by a pediatric
endocrinologist. Learning how to accurately measure
children and adolescents is beyond the scope of this review,
but includes removing shoes, correct positioning of the
child, and correctly plotting their heights and weights on a
gender-appropriate growth chart. This is critical to early
recognition of a growth disorder. Careful assessment of
growth velocity should also be done. Initial evaluation
includes taking a full medical history, including family and
perinatal history. A nutritional history is important because
malnutrition can be associated with low levels of IGF-1 in
the presence of normal or increased GH secretion [11].
Laboratory testing consists of screening studies, including
markers of liver and kidney function, electrolytes, com-
plete blood count (CBC), sedimentation rate, urinalysis,
celiac disease screen, cortisol level, thyroid function
evaluation, IGF-1 and IGFBP-3 levels, and chromosome
analysis. An x-ray (bone age) of the left hand and wrist
should be taken and an estimation compared to chrono-
logical age will be determined to allow assessment of the
window of opportunity for growth—the ‘younger’ or more
delayed the bone maturation, the more growth potential a
child has, although a bone age determination does not
reveal the cause of the growth disorder.
IGF-1 and IGFBP-3 measurements are part of the initial
evaluation to help diagnose SPIGFD. If IGF-1 is low, GH
stimulation testing should be done. If there is evidence of
GH deficiency (secondary IGF-1 deficiency), an magnetic
resonance image (MRI) of the brain, with attention to the
pituitary-hypothalamic area, is indicated to consider
structural abnormalities in the region (i.e. craniopharyngi-
oma, optic glioma, sarcoidosis, hypophysitis, hemorrhage,
or infarct, etc.). Normal GH secretion in the presence of
low IGF-1 suggests primary IGF-1 deficiency. If a diag-
nosis of SPIGFD is confirmed, IGF-1 replacement therapy
should be initiated with mecasermin [6].
Children treated with GH who have a poor response to
treatment, defined as a suboptimal growth response [12]
and a failure to increase IGF-1 levels, should be re-eval-
uated to determine if they meet the diagnostic criteria for
SPIGFD (i.e. height and IGF-1 less than or equal to -3
SDS, normal GH secretion, after poor compliance with
scheduled GH injections has been ruled out). In cases
where compliance is a question, the recombinant human
GH (rhGH) should be administered by a reliable source.
3 The IGF-1 Generation Test
The principle behind the design of the IGF-1 Generation
Test (IGFGT) was that repeated injections of human GH
induce measurable increases in IGF-1, IGFBP-3 and ALS
secretion. However, in GH-deficient patients, the degree of
IGF-1 response did not convincingly predict the growth
response to GH therapy [13]. Because of this, the IGFGT is
primarily a research tool. Performing the IGFGT is not
necessary to make a diagnosis of SPIGFD, nor should it be
required to begin mecasermin replacement; meeting the
less than or equal to -3 height and IGF-1 SDS criteria in
the setting of normal-to-high GH is sufficient to make the
diagnosis of SPIGFD.
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4 Treatment
4.1 IGF-1 (Mecasermin rDNA) Administration
Once a diagnosis of SPIGFD has been made, it is important
to begin treatment with mecasermin as soon as possible.
Growth rates are highest during the first year of treatment
[6], and both first-year catch-up growth and long-term
outcomes, such as adult height, are better when therapy is
initiated in younger children at an appropriate dose [10,
14]. Treatment with mecasermin involves twice-daily
injections [6], ideally over a period of years to maximize adult
height, and compliance is crucial to achieve both optimal
growth outcomes and safety. In our practices, treatment
therefore begins with extensive family discussions.
4.2 Side Effects
Patients and caregivers must be familiar with all the risks
and benefits of treatment, especially with regard to com-
mon side effects of mecasermin, including symptoms of
hypoglycemia. The most common side effects of meca-
sermin therapy are listed below [6].
• Hypoglycemia is often present before treatment in
patients with SPIGFD, particularly young children with
the phenotype of Laron syndrome [15]. Treatment with
mecasermin may exacerbate this, especially during the
early stages of therapy. Information about the occur-
rence of hypoglycemia should be sought even before
beginning mecasermin. The dose of mecasermin should
be increased more slowly in children with a prior
history of hypoglycemia. Younger patients, who may
have difficulty articulating symptoms, should be mon-
itored carefully during the treatment initiation phase.
Hypoglycemic episodes are minimized through ade-
quate carbohydrate (or caloric) intake along with each
injection and by avoiding overdose; we advise admin-
istration within 20 min of a meal or snack [6], and
provide training in dose calculation and delivery.
• Injection site reactions may be avoided or minimized
by alternation of injection site among the upper arm,
thigh, buttock, and abdomen, and by the following
techniques: avoiding the use of ultra-short needles;
removing mecasermin from the refrigerator at least
20 min before injecting; and cleaning the site using
soap and water instead of alcohol.
• Lymphoid tissue overgrowth may occur, including
enlarged tonsils/adenoids (which may require tonsil-
lectomy), snoring, and middle-ear effusion (which
occasionally requires tympanostomy tube placement).
• Headaches While some headaches may be associated
with normal childhood illnesses, we advise parents to
report any prolonged, unusual headaches to their
healthcare professional as soon as possible in order to
allow the child to be evaluated for possible intracranial
hypertension.
• Craniofacial growth, sometimes with coarsening of
facial features, may occur during treatment with IGF-1.
The results appear to soften with time, especially after
completion of linear growth and subsequent discontin-
uation of mecasermin. [10, 14] This coarsening is due
to soft tissue growth and does not represent bony
overgrowth, such as is seen in acromegaly [14].
Obesity is well-recognized in pubertal and adult patients
with untreated Laron syndrome, and the relationship of
obesity to mecasermin treatment is not clear [16].
4.3 Dose of Mecasermin
The FDA-approved initial dosing is from 0.04 to 0.08 mg/
kg/dose twice daily given for at least 1 week [6]. If the
initial dose is well-tolerated, the dose is increased by
0.04 mg/kg/dose, up to a maximum of 0.12 mg/kg/dose. It
is important to achieve a stable therapeutic dose as quickly
as possible (ideally within 1 month), as both first-year
growth and long-term outcomes are best at doses C0.1 mg/
kg/dose given twice daily [10]. Younger children, espe-
cially those with a history of hypoglycemia, are generally
started at a dose in the lower bound of the starting range
(e.g. 0.04 mg/kg/dose) and the dose is increased more
slowly. Once a stable dose in the efficacious range is
achieved, it is important to monitor the patient’s weight to
make sure they do not outgrow their dose. That is, as the
patient gains weight, it is critical to also adjust the dose so
the patient remains in the most effective dose range. Also,
if mecasermin treatment is interrupted for an extended
period (e.g. due to a drug shortage), the patients should be
reassessed to determine their need for resumption of
mecasermin therapy, and if the patients still have growth
potential, mecasermin dose escalation should likely be
undertaken similar to when the drug was originally initi-
ated. Data on this scenario are limited, and judgment of the
treating physician is critical. For those children who
experienced hypoglycemia or other drug-related adverse
events while on mecasermin, we would recommend
repeating the schedule of sequential dose increases that was
followed originally when they reinitiate the drug.
4.4 Monitoring Treatment
Determination of IGF-1 levels during mecasermin treat-
ment is of limited value [6] and we do not recommend
measuring them as part of routine care. They can be of
value when compliance with prescribed injections is a
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concern (administering an observed injection in the office
followed by a serum IGF-1 level 2 h later would be helpful
in this situation).
4.5 Duration of Treatment
Treatment should continue until the epiphyses fuse and full
growth potential has been achieved. During the course of
treatment we monitor patients at regular intervals to check
both the progress of growth and occurrence of side effects.
Treatment efficacy is assessed through careful monitoring
of the growth chart and patient examination. As noted
above, substantial catch-up growth may occur with early
achievement of a stable therapeutic dose. To maintain
efficacy, the dose of mecasermin should be adjusted for
weight gain at regular intervals as growth progresses.
Treating physicians should be aware that the typical growth
response to mecasermin in SPIGFD is not as robust as the
response to GH in patients with GH deficiency.
4.6 Use of Gonadotropin-Releasing Hormone
Analogues to Delay Puberty
There have been no randomized controlled studies of this
question. Some children in the mecasermin pivotal study
(described by both Chernausek et al. [10] and Backeljauw
et al. [14]) did receive these agents. There was no statis-
tically significant difference in adult height between those
who were treated with gonadotropin-releasing hormone
(GnRH) analogues and those who were not, although it is
biologically plausible that combination therapy of meca-
sermin with GnRH analogues may improve height in
SPIGFD patients if the GnRH analogues are started at the
onset of puberty [14]. In our opinion, the best way to avoid
the issue of puberty leading to truncation of height gain is
to begin mecasermin treatment as early as possible, with
the caveat that the safety and effectiveness of mecasermin
treatment has not been established in pediatric patients
below the age of 2 years.
5 Conclusion
This article illustrates how the diagnosis of patients with
SPIGFD is determined and how this condition can be
effectively treated with mecasermin. It is very important to
have careful discussions with the family prior to treatment
initiation to discuss the necessity of being compliant over
the long-term course of therapy, and to educate the family
about potential adverse effects. It is also critical when
initiating therapy to promptly escalate the dose to the
efficacious range [0.1 mg/kg/dose given twice daily, as
symptoms allow, and to adjust the dose over time to
account for increases in weight as the patient grows.
Finally, for patients who had to stop mecasermin as a result
of the drug shortage, consideration should be given to re-
initiating the original dose escalation scheme when the
drug is resumed.
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